Elidel
(Pimecrolimus)ApprovedSmall molecule
Pimecrolimus is used to treat eczema (atopic dermatitis) and other inflammatory skin conditions by reducing itching, redness, and inflammation when applied as a cream to affected areas of the skin.[2] Elidel is currently approved and in use across 12 indications[4].[1]
Elidel is one of 118 small molecule programs targeting Atopic Eczema. It is currently in Approved.
12
Indications
28
Total Trials
2
Active Trials
117
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 11 indications
Competition
Competitive Landscape
127 competitors in Atopic Dermatitis
#DrugCompanyPhaseTrials
1Elidel
BBausch Health Americas, Inc.
Approved
Cytosar
TevaPhase 3
Fludara
SanofiPhase 3
Adtralza
LEO PharmaPhase 3
Amlitelimab
SanofiPhase 3
Certolizumab
Johnson & JohnsonPhase 3
DUPIXENT
RegeneronPhase 3
Jaktinib
SSuzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3
ICP-332
BBeijing InnoCare Pharma Tech Co., Ltd.
Phase 3
VC005
JJiangsu vcare pharmaceutical technology co., LTD
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atopic Dermatitis16 trials
Combination Therapy for Atopic Dermatitis
Completed·—·Phase 4·NCT00119158·90 enrolled
Show 13 more trials
Oral Lichen Planus2 trials
Keratoconjunctivitis sicca1 trial
7 more indications
Vulvar Lichen Sclerosus1 trial
Children1 trial
Safety and Efficacy1 trial
Atopic1 trial
Regulatory
FDA Approval Timeline[5]
Dec 13, 2001
ELIDEL
NDA NDA021302
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Elidel drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Pimecrolimus. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- FK506-Binding Protein 1a Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- BBausch Health Americas, Inc.